Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: A case report

Transfusion

Volumn 54, Issue 8, 2014, Pages 2064-2067

  Yates, Sean ^a   Matevosyan, Karen ^a   Rutherford, Cynthia ^a   Shen, Yu Min ^a   Sarode, Ravi ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CREATININE; CYCLOPHOSPHAMIDE; HEMOGLOBIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VANCOMYCIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTICLE; BACTERIUM CULTURE; BLOOD CULTURE; BONE MARROW SUPPRESSION; CASE REPORT; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL DISCHARGE; HUMAN; INTERSTITIAL LUNG DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG FUNCTION; LUNG TOXICITY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PLASMAPHERESIS; RELAPSE; REMISSION; SIDE EFFECT; STAPHYLOCOCCUS EPIDERMIDIS; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE;

ADAM PROTEINS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BORONIC ACIDS; CYCLOPHOSPHAMIDE; DRUG RESISTANCE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; PYRAZINES; RECURRENCE; REMISSION INDUCTION; STAPHYLOCOCCAL INFECTIONS;

EID: 84906225926     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12614     Document Type: Article

References (14)

1. Tsai HM, Lian EC,. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
2. Jin M, Casper TC, Cataland SR, et al. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol 2008; 141: 651-658.
3. Tsai HM,. Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management. Semin Thromb Hemost 2012; 38: 469-482.
4. Shortt J, Oh DH, Opat SS,. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med 2013; 368: 90-92.
5. Elliott MA, Heit JA, Pruthi RK, et al. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol 2009; 83: 365-372.
6. Patino W, Sarode R,. Successful repeat therapy with rituximab for relapsed thrombotic thrombocytopenic purpura. J Clin Apher 2007; 22: 17-20.
7. Balen T, Schreuder MF, Jong H, et al. Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib. Eur J Haematol 2014; 92: 80-82.
8. Painuly U, Kumar S,. Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. Clin Med Insights Oncol 2013; 7: 53-73.
9. Mulder A, Heidt S, Vergunst M, et al. Proteasome inhibition profoundly affects activated human B cells. Transplantation 2013; 95: 1331-1337.
10. Park SJ, Cheong HI, Shin JI,. Antibody depletion by bortezomib through blocking of antigen presentation. N Engl J Med 2013; 368: 1364-1365.
11. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754-1761.
12. Paterno F, Shiller M, Tillery G, et al. Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 2012; 12: 2526-2531.
13. Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118: 1746-1753.
14. Utecht K, Kolesar J,. Bortezomib: a novel chemotherapeutic agent for hematologic malignancies. Am J Health Syst Pharm 2008; 65: 1221-1231.